All In MedTech

Device Trial Radar · NCT02922972

Treatment of Keloid Scar by Autologous Platelet Rich Plasma Obtained With RgenKit-BCT

Efficay of Autologous Platelet Rich Plasma Obtained With RgenKit-BCT in the Prevention and the Treatment of Keloid Scars

Last checked: Nov 19, 2026Latest source record: Nov 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Sep 2014

Primary completion

Sep 2017

Study completion Sep 2017

Sponsor

Lead sponsor
Regen Lab SANot on our public-company list
Sponsor type
Industry
First posted
Oct 4, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this prospective study is to assess the efficacy of autologous Platelet Rich Plasma prepared with RegenKit-BCT in the prevention and the treatment of keloid scars refractory to conventional treatments. Fifteen patients were included and received three PRP injection sessions with a one-month interval. The outcomes were assessed at baseline (before treatment), 3, 6, 12 and 24 months after the last injection session. Safety was assessed by reported adverse event analysis.

Conditions

  • Keloid

Interventions

  • Autologous Platelet Rich Plasma obtained with RegenKit®-BCTDevice

    After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients achieving a complete remission of their keloid scar 2 years after the end of treatment.Time frame: 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.